CalciMedica Announces Presentations at Upcoming Medical Meetings
CalciMedica (Nasdaq: CALC) announced two upcoming presentations of its Phase 2b CARPO trial results for Auxora™ in Acute Pancreatitis. The first is a plenary presentation by Prof. Robert Sutton at the American Pancreatic Association (APA) 2024 Annual Meeting in Maui on December 10, focusing on how Auxora reduces severe organ failure in patients with acute pancreatitis and SIRS.
The second is a poster presentation at the Emergencies in Medicine (EIM) 2024 Meeting in Maui, highlighting the randomized, double-blind, placebo-controlled dose-ranging study. Both presentations will be available on CalciMedica's IR website after the sessions.
CalciMedica (Nasdaq: CALC) ha annunciato due prossime presentazioni dei risultati del suo trial di Fase 2b CARPO per Auxora™ in Pancre atite Acuta. La prima è una presentazione plenaria del Prof. Robert Sutton al Meeting Annuale dell'American Pancreatic Association (APA) 2024 a Maui il 10 dicembre, incentrata su come Auxora riduce il fallimento organico grave nei pazienti con pancreatite acuta e SIRS.
La seconda è una presentazione di poster al Meeting Emergencies in Medicine (EIM) 2024 a Maui, evidenziando lo studio randomizzato, in doppio cieco e controllato con placebo per la determinazione del dosaggio. Entrambe le presentazioni saranno disponibili sul sito IR di CalciMedica dopo le sessioni.
CalciMedica (Nasdaq: CALC) anunció dos próximas presentaciones de los resultados de su ensayo Fase 2b CARPO para Auxora™ en Pancreatitis Aguda. La primera es una presentación plenaria del Prof. Robert Sutton en la Reunión Anual de la American Pancreatic Association (APA) 2024 en Maui el 10 de diciembre, centrándose en cómo Auxora reduce la falla orgánica severa en pacientes con pancreatitis aguda y SIRS.
La segunda es una presentación de póster en la Reunión Emergencias en Medicina (EIM) 2024 en Maui, destacando el estudio aleatorizado, doble ciego y controlado con placebo sobre la determinación de dosis. Ambas presentaciones estarán disponibles en el sitio web de IR de CalciMedica después de las sesiones.
CalciMedica (Nasdaq: CALC)는 급성 췌장염 치료를 위한 Auxora™의 2b 단계 CARPO 시험 결과 발표 예정 두 건을 발표했습니다. 첫 번째는 12월 10일 마우이에서 열리는 2024 미국 췌장학회(APA) 연례 회의에서 로버트 섯턴 교수의 기조 발표로, Auxora가 급성 췌장염 및 SIRS 환자의 중증 장기 부전을 어떻게 감소시키는지에 초점을 맞춥니다.
두 번째는 마우이에서 열리는 2024 의학 응급상황(EIM) 회의에서의 포스터 발표로, 무작위, 이중 맹검, 위약 대조 용량 결정 연구를 강조합니다. 두 발표 모두 세션 이후 CalciMedica의 IR 웹사이트에서 확인할 수 있습니다.
CalciMedica (Nasdaq: CALC) a annoncé deux prochaines présentations des résultats de son essai de Phase 2b CARPO pour Auxora™ dans le cadre de la Pancréatite Aiguë. La première est une présentation plénière par le Prof. Robert Sutton lors de la Réunion Annuelle de l'American Pancreatic Association (APA) 2024 à Maui le 10 décembre, mettant l'accent sur la façon dont Auxora réduit l'insuffisance organique sévère chez les patients atteints de pancréatite aiguë et de SIRS.
La deuxième est une présentation d'affiche lors de la Réunion des Urgences en Médecine (EIM) 2024 à Maui, mettant en lumière l'étude randomisée, en double aveugle et contrôlée par placebo. Les deux présentations seront disponibles sur le site IR de CalciMedica après les sessions.
CalciMedica (Nasdaq: CALC) hat zwei bevorstehende Präsentationen der Ergebnisse seiner Phase 2b CARPO-Studie für Auxora™ bei akuter Pankreatitis angekündigt. Die erste ist eine Plenarvortrag von Prof. Robert Sutton auf dem Jahrestreffen der American Pancreatic Association (APA) 2024 in Maui am 10. Dezember, wobei der Fokus darauf liegt, wie Auxora das schwere Organversagen bei Patienten mit akuter Pankreatitis und SIRS reduziert.
Die zweite Präsentation ist ein Poster im Rahmen des Meetings für Notfälle in der Medizin (EIM) 2024 in Maui und hebt die randomisierte, doppelblinde, placebo-kontrollierte Dosisstudie hervor. Beide Präsentationen werden nach den Sitzungen auf der IR-Website von CalciMedica verfügbar sein.
- None.
- None.
Prof. Robert Sutton to deliver plenary presentation on Phase 2b CARPO trial of Auxora™ in Acute Pancreatitis (AP) at American Pancreatic Association (APA) 2024 Annual Meeting
Poster presentation on Phase 2b CARPO trial at Emergencies in Medicine (EIM) 2024 Meeting
Details for the presentations are as follows:
Plenary Presentation at APA 2024 Annual Meeting
Presentation Title: Auxora Decreases the Development of Severe Organ Failure in Patients with Acute Pancreatitis and SIRS
Presenter: Prof. Robert Sutton, B.A. (Hons), M.B., B.S., D.Phil., FRCS, University of Liverpool and Liverpool University Hospitals NHS Foundation Trust
Session Title: Abstract Session 2 – Pancreatitis
Session Date and Time: Tuesday, December 10, 8:00-9:30 a.m. HST
Poster Presentation at EIM 2024 Meeting
Presentation Title: A Randomized, Double-Blind, Placebo Controlled Dose Ranging Study of Auxora in Patients with Acute Pancreatitis (AP) and Accompanying Systemic Inflammatory Response Syndrome (SIRS)- CARPO (NCT0468106)
The presentation and poster will be available following the sessions on the Medical Events & Presentations section of CalciMedica's IR website at https://ir.calcimedica.com/news-events/medical-events-publications.
About CalciMedica
CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora™ has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials. CalciMedica has announced topline data for a Phase 2b trial (called CARPO – NCT04681066) in patients with acute pancreatitis (AP) and accompanying systemic inflammatory response syndrome (SIRS) and completed a Phase 2 trial (called CARDEA – NCT04345614) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE – NCT06374797) in patients with acute kidney disease (AKI) with associated acute hypoxemic respiratory failure (AHRF) with data expected in 2025 and continuing to support the ongoing Phase 1/2 trial (called CRSPA – NCT04195347) in pediatric patients with asparaginase-induced pancreatic toxicity (AIPT) with data expected in 2025. CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, CA. For more information, please visit www.calcimedica.com.
Forward-Looking Statements
This communication contains forward-looking statements which include, but are not limited to, CalciMedica's ongoing and planned clinical trials and the timing, design, expected patient enrollment thereof and the expected timing for the release of data from those trials, including its Phase 2b CARPO trial of Auxora for AP with accompanying SIRS, its ongoing Phase 1/2 CRSPA trial of Auxora in pediatric patients with AIPT, and its planned Phase 2 KOURAGE trial of Auxora in AKI with associated AHRF; the potential benefits of Auxora for the treatment of AP, AKI and AIPT; and the potential of CalciMedica's proprietary technology to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. CalciMedica's expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks, and changes in circumstances. Risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption "Risk Factors" in CalciMedica's Annual Report on Form 10-K for the year ended December 31, 2023, and elsewhere in CalciMedica's subsequent reports on Form 10-K, Form 10-Q or Form 8-K filed with the SEC from time to time and available at www.sec.gov. These documents can be accessed on CalciMedica's web page at ir.calcimedica.com/financials-filings/sec-filings. The forward-looking statements contained herein are made as of the date hereof, and CalciMedica undertakes no obligation to update them after this date, except as required by law.
CalciMedica Contact:
Investors and Media
Argot Partners
Sarah Sutton/Kevin Murphy
calcimedica@argotpartners.com
(212) 600-1902
View original content to download multimedia:https://www.prnewswire.com/news-releases/calcimedica-announces-presentations-at-upcoming-medical-meetings-302312062.html
SOURCE CalciMedica, Inc.
FAQ
When will CalciMedica (CALC) present its Auxora Phase 2b CARPO trial results at APA 2024?
What are the key findings of CalciMedica's (CALC) Auxora trial in acute pancreatitis?
Where can investors find CalciMedica's (CALC) Auxora trial presentations after the events?
What medical conferences will feature CalciMedica's (CALC) Auxora research in December 2024?
